Registro:

Referencias:

• Cannavo, S., Messina, E., Albani, A., Ferrau, F., Barresi, V., Priola, S., Clinical management of critically ill patients with Cushing's disease due to ACTH-secreting pituitary macroadenomas: effectiveness of presurgical treatment with pasireotide (2016) Endocrine, 52 (3), pp. 481-487
• Lamos, E.M., Munir, K.M., Cushing disease: highlighting the importance of early diagnosis for both de novo and recurrent disease in light of evolving treatment patterns (2014) Endocr Pract, 20 (9), pp. 945-955
• Simeoli, C., Auriemma, R.S., Tortora, F., De Leo, M., Iacuaniello, D., Cozzolino, A., The treatment with pasireotide in Cushing's disease: effects of long-term treatment on tumor mass in the experience of a single center (2015) Endocrine, 50 (3), pp. 725-740
• Newell-Price, J., Bertagna, X., Grossman, A.B., Nieman, L.K., Cushing's syndrome (2006) Lancet, 367 (9522), pp. 1605-1617
• Steffensen, C., Bak, A.M., Rubeck, K.Z., Jorgensen, J.O., Epidemiology of Cushing's syndrome (2010) Neuroendocrinology, 92, pp. 1-5
• Feelders, R.A., Hofland, L.J., Medical treatment of Cushing's disease (2013) J Clin Endocrinol Metab, 98 (2), pp. 425-438
• Fleseriu, M., Petersenn, S., New avenues in the medical treatment of Cushing's disease: corticotroph tumor targeted therapy (2013) J Neurooncol, 114 (1), pp. 1-11
• Becker, G., Kocher, M., Kortmann, R.D., Paulsen, F., Jeremic, B., Muller, R.P., Radiation therapy in the multimodal treatment approach of pituitary adenoma (2002) Strahlenther Onkol, 178 (4), pp. 173-186
• Tritos, N.A., Biller, B.M., Advances in medical therapies for Cushing's syndrome (2012) Discov Med, 13 (69), pp. 171-179
• van der Pas, R., de Herder, W.W., Hofland, L.J., Feelders, R.A., New developments in the medical treatment of Cushing's syndrome (2012) Endocr Relat Cancer, 19 (6), pp. R205-R223
• Langlois, F., McCartney, S., Fleseriu, M., Recent progress in the medical therapy of pituitary tumors (2017) Endocrinol Metab (Seoul), 32 (2), pp. 162-170
• Colao, A., Petersenn, S., Newell-Price, J., Findling, J.W., Gu, F., Maldonado, M., A 12-month phase 3 study of pasireotide in Cushing's disease (2012) N Engl J Med, 366 (10), pp. 914-924
• Petersenn, S., Salgado, L.R., Schopohl, J., Portocarrero-Ortiz, L., Arnaldi, G., Lacroix, A., Long-term treatment of Cushing's disease with pasireotide: 5-year results from an open-label extension study of a phase III trial (2017) Endocrine, 57 (1), pp. 156-165
• Lacroix, A., Gu, F., Gallardo, W., Pivonello, R., Yu, Y., Witek, P., Efficacy and safety of once-monthly pasireotide in Cushing's disease: a 12 month clinical trial (2018) Lancet Diabetes Endocrinol, 6 (1), pp. 17-26
• Godbout, A., Manavela, M., Danilowicz, K., Beauregard, H., Bruno, O.D., Lacroix, A., Cabergoline monotherapy in the long-term treatment of Cushing's disease (2010) Eur J Endocrinol, 163 (5), pp. 709-716
• Burman, P., Eden-Engstrom, B., Ekman, B., Karlsson, F.A., Schwarcz, E., Wahlberg, J., Limited value of cabergoline in Cushing's disease: a prospective study of a 6-week treatment in 20 patients (2016) Eur J Endocrinol, 174 (1), pp. 17-24
• Ferriere, A., Cortet, C., Chanson, P., Delemer, B., Caron, P., Chabre, O., Cabergoline for Cushing's disease: a large retrospective multicenter study (2017) Eur J Endocrinol, 176 (3), pp. 305-314
• Pecori Giraldi, F., Scaroni, C., Arvat, E., Martin, M., Giordano, R., Albiger, N., Effect of protracted treatment with rosiglitazone, a PPARgamma agonist, in patients with Cushing's disease (2006) Clin Endocrinol (Oxf), 64 (2), pp. 219-224
• Castinetti, F., Guignat, L., Giraud, P., Muller, M., Kamenicky, P., Drui, D., Ketoconazole in Cushing's disease: is it worth a try? (2014) J Clin Endocrinol Metab, 99 (5), pp. 1623-1630
• Daniel, E., Aylwin, S., Mustafa, O., Ball, S., Munir, A., Boelaert, K., Effectiveness of metyrapone in treating Cushing's syndrome: a retrospective multicenter study in 195 patients (2015) J Clin Endocrinol Metab, 100 (11), pp. 4146-4154
• Baudry, C., Coste, J., Bou Khalil, R., Silvera, S., Guignat, L., Guibourdenche, J., Efficiency and tolerance of mitotane in Cushing's disease in 76 patients from a single center (2012) Eur J Endocrinol, 167 (4), pp. 473-481
• Fleseriu, M., Biller, B.M., Findling, J.W., Molitch, M.E., Schteingart, D.E., Gross, C., Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome (2012) J Clin Endocrinol Metab, 97 (6), pp. 2039-2049
• Bertagna, X., Pivonello, R., Fleseriu, M., Zhang, Y., Robinson, P., Taylor, A., LCI699, a potent 11beta-hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushing's disease: results from a multicenter, proof-of-concept study (2014) J Clin Endocrinol Metab, 99 (4), pp. 1375-1383
• Pecori Giraldi, F., Ambrogio, A.G., Andrioli, M., Sanguin, F., Karamouzis, I., Corsello, S.M., Potential role for retinoic acid in patients with Cushing's disease (2012) J Clin Endocrinol Metab, 97 (10), pp. 3577-3583
• Vilar, L., Albuquerque, J.L., Lyra, R., Trovao Diniz, E., Rangel Filho, F., Gadelha, P., The role of isotretinoin therapy for Cushing's disease: results of a prospective study (2016) Int J Endocrinol, 2016
• Boscaro, M., Ludlam, W.H., Atkinson, B., Glusman, J.E., Petersenn, S., Reincke, M., Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial (2009) J Clin Endocrinol Metab, 94 (1), pp. 115-122
• Stalla, G.K., Brockmeier, S.J., Renner, U., Newton, C., Buchfelder, M., Stalla, J., Octreotide exerts different effects in vivo and in vitro in Cushing's disease (1994) Eur J Endocrinol, 130 (2), pp. 125-131
• Cuevas-Ramos, D., Lim, D.S.T., Fleseriu, M., Update on medical treatment for Cushing's disease (2016) Clin Diabetes Endocrinol, 2, p. 16
• de Bruin, C., Feelders, R.A., Waaijers, A.M., van Koetsveld, P.M., Sprij-Mooij, D.M., Lamberts, S.W., Differential regulation of human dopamine D2 and somatostatin receptor subtype expression by glucocorticoids in vitro (2009) J Mol Endocrinol, 42 (1), pp. 47-56
• Feelders, R.A., de Bruin, C., Pereira, A.M., Romijn, J.A., Netea-Maier, R.T., Hermus, A.R., Pasireotide alone or with cabergoline and ketoconazole in Cushing's disease (2010) N Engl J Med, 362 (19), pp. 1846-1848
• Ceccato, F., Scaroni, C., Boscaro, M., Clinical use of pasireotide for Cushing's disease in adults (2015) Ther Clin Risk Manag, 11, pp. 425-434
• Fleseriu, M., Petersenn, S., Medical management of Cushing's disease: what is the future? (2012) Pituitary, 15 (3), pp. 330-341
• Colao, A., De Block, C., Gaztambide, M.S., Kumar, S., Seufert, J., Casanueva, F.F., Managing hyperglycemia in patients with Cushing's disease treated with pasireotide: medical expert recommendations (2014) Pituitary, 17 (2), pp. 180-186
• Pivonello, R., Ferone, D., de Herder, W.W., Kros, J.M., De Caro, M.L., Arvigo, M., Dopamine receptor expression and function in corticotroph pituitary tumors (2004) J Clin Endocrinol Metab, 89 (5), pp. 2452-2462
• Barbot, M., Albiger, N., Ceccato, F., Zilio, M., Frigo, A.C., Denaro, L., Combination therapy for Cushing's disease: effectiveness of two schedules of treatment: should we start with cabergoline or ketoconazole? (2014) Pituitary, 17 (2), pp. 109-117
• Heaney, A.P., Fernando, M., Yong, W.H., Melmed, S., Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas (2002) Nat Med, 8 (11), pp. 1281-1287
• Stone, J.C., Furuya-Kanamori, L., Barendregt, J.J., Doi, S.A., Was there really any evidence that rosiglitazone increased the risk of myocardial infarction or death from cardiovascular causes? (2015) Pharmacoepidemiol Drug Saf, 24 (3), pp. 223-227
• Daniel, E., Newell-Price, J.D., Therapy of endocrine disease: steroidogenesis enzyme inhibitors in Cushing's syndrome (2015) Eur J Endocrinol, 172 (6), pp. R263-R280
• Pivonello, R., De Leo, M., Cozzolino, A., Colao, A., The treatment of Cushing's disease (2015) Endocr Rev, 36 (4), pp. 385-486
• Fleseriu, M., Castinetti, F., Updates on the role of adrenal steroidogenesis inhibitors in Cushing's syndrome: a focus on novel therapies (2016) Pituitary, 19 (6), pp. 643-653
• Rigel, D.F., Fu, F., Beil, M., Hu, C.W., Liang, G., Jeng, A.Y., Pharmacodynamic and pharmacokinetic characterization of the aldosterone synthase inhibitor FAD286 in two rodent models of hyperaldosteronism: comparison with the 11beta-hydroxylase inhibitor metyrapone (2010) J Pharmacol Exp Ther, 334 (1), pp. 232-243
• Nieman, L.K., Biller, B.M., Findling, J.W., Murad, M.H., Newell-Price, J., Savage, M.O., Treatment of Cushing's syndrome: an endocrine society clinical practice guideline (2015) J Clin Endocrinol Metab, 100 (8), pp. 2807-2831
• Preda, V.A., Sen, J., Karavitaki, N., Grossman, A.B., Etomidate in the management of hypercortisolaemia in Cushing's syndrome: a review (2012) Eur J Endocrinol, 167 (2), pp. 137-143
• Bertagna, X., Guignat, L., Groussin, L., Bertherat, J., Cushing's disease (2009) Best Pract Res Clin Endocrinol Metab, 23 (5), pp. 607-623
• Feelders, R.A., Hofland, L.J., de Herder, W.W., Medical treatment of Cushing's syndrome: adrenal-blocking drugs and ketaconazole (2010) Neuroendocrinology, 92, pp. 111-115
• Igaz, P., Tombol, Z., Szabo, P.M., Liko, I., Racz, K., Steroid biosynthesis inhibitors in the therapy of hypercortisolism: theory and practice (2008) Curr Med Chem, 15 (26), pp. 2734-2747
• Bourgeois, S., Pfahl, M., Baulieu, E.E., DNA binding properties of glucocorticosteroid receptors bound to the steroid antagonist RU-486 (1984) EMBO J, 3 (4), pp. 751-755
• Johanssen, S., Allolio, B., Mifepristone (RU 486) in Cushing's syndrome (2007) Eur J Endocrinol, 157 (5), pp. 561-569
• Fleseriu, M., Pivonello, R., Young, J., Hamrahian, A.H., Molitch, M.E., Shimizu, C., Osilodrostat, a potent oral 11beta-hydroxylase inhibitor: 22-week, prospective, phase II study in Cushing's disease (2016) Pituitary, 19 (2), pp. 138-148
• Guelho, D., Grossman, A.B., Emerging drugs for Cushing's disease (2015) Expert Opin Emerg Drugs, 20 (3), pp. 463-478
• Salvatori, R., DelConte, A., Geer, E.B., Koziol, T., Jorkasky, D., (2015) An open-label study to assess the safety and efficacy of levoketoconazole (COR-003) in the treatment of endogenous Cushing's syndrome, , Endocrine Society's 97th Annual Meeting and Expo. San Diego
• Liu, N.A., Jiang, H., Ben-Shlomo, A., Wawrowsky, K., Fan, X.M., Lin, S., Targeting zebrafish and murine pituitary corticotroph tumors with a cyclin-dependent kinase (CDK) inhibitor (2011) Proc Natl Acad Sci U S A, 108 (20), pp. 8414-8419
• Liu, N.A., Araki, T., Cuevas-Ramos, D., Hong, J., Ben-Shlomo, A., Tone, Y., Cyclin E-mediated human proopiomelanocortin regulation as a therapeutic target for Cushing disease (2015) J Clin Endocrinol Metab, 100 (7), pp. 2557-2564
• Fukuoka, H., Cooper, O., Ben-Shlomo, A., Mamelak, A., Ren, S.G., Bruyette, D., EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas (2011) J Clin Invest, 121 (12), pp. 4712-4721
• Ben-Shlomo, A., Cooper, O., Role of tyrosine kinase inhibitors in the treatment of pituitary tumours: from bench to bedside (2017) Curr Opin Endocrinol Diabetes Obes, 24 (4), pp. 301-305
• Halem, H.A., Ufret, M., Jewett, I., Mattei, A., Bastille, A., Beech, J., (2016) In vivo suppression of corticosterone in rodent models of Cushing's disease with a selective, peptide MC2 receptor antagonist, , Endocrine Society's 98th Annual Meeting and Expo. Boston
• Culler, M.D., Somatostatin-dopamine chimeras: a novel approach to treatment of neuroendocrine tumors (2011) Horm Metab Res, 43 (12), pp. 854-857
• Ibanez-Costa, A., Lopez-Sanchez, L.M., Gahete, M.D., Rivero-Cortes, E., Vazquez-Borrego, M.C., Galvez, M.A., BIM-23A760 influences key functional endpoints in pituitary adenomas and normal pituitaries: molecular mechanisms underlying the differential response in adenomas (2017) Sci Rep, 7, p. 42002
• Bode, H., Seiz, M., Lammert, A., Brockmann, M.A., Back, W., Hammes, H.P., SOM230 (pasireotide) and temozolomide achieve sustained control of tumour progression and ACTH secretion in pituitary carcinoma with widespread metastases (2010) Exp Clin Endocrinol Diabetes, 118 (10), pp. 760-763
• Dillard, T.H., Gultekin, S.H., Delashaw, J.B., Jr., Yedinak, C.G., Neuwelt, E.A., Fleseriu, M., Temozolomide for corticotroph pituitary adenomas refractory to standard therapy (2011) Pituitary, 14 (1), pp. 80-91
• Liu, J.K., Patel, J., Eloy, J.A., The role of temozolomide in the treatment of aggressive pituitary tumors (2015) J Clin Neurosci, 22 (6), pp. 923-929
• Fernando, M.A., Heaney, A.P., Alpha1-adrenergic receptor antagonists: novel therapy for pituitary adenomas (2005) Mol Endocrinol, 19 (12), pp. 3085-3096
• Qian, Z.R., Asa, S.L., Siomi, H., Siomi, M.C., Yoshimoto, K., Yamada, S., Overexpression of HMGA2 relates to reduction of the let-7 and its relationship to clinicopathological features in pituitary adenomas (2009) Mod Pathol, 22 (3), pp. 431-441
• Ortiz, L.D., Syro, L.V., Scheithauer, B.W., Ersen, A., Uribe, H., Fadul, C.E., Anti-VEGF therapy in pituitary carcinoma (2012) Pituitary, 15 (3), pp. 445-449
• Ferone, D., Pivonello, C., Vitale, G., Zatelli, M.C., Colao, A., Pivonello, R., Molecular basis of pharmacological therapy in Cushing's disease (2014) Endocrine, 46 (2), pp. 181-198
• Du, L., Bergsneider, M., Mirsadraei, L., Young, S.H., Jonker, J.W., Downes, M., Evidence for orphan nuclear receptor TR4 in the etiology of Cushing disease (2013) Proc Natl Acad Sci U S A, 110 (21), pp. 8555-8560
• Labeur, M., Paez-Pereda, M., Arzt, E., Stalla, G.K., Potential of retinoic acid derivatives for the treatment of corticotroph pituitary adenomas (2009) Rev Endocr Metab Disord, 10 (2), pp. 103-109
• Hyams, M.N., Gallaher, P.D., Vitamin A therapy in the treatment of vulvar leucoplakia (1950) Am J Obstet Gynecol, 59 (6), pp. 1346-1354
• Zhang, C., Duvic, M., Retinoids: therapeutic applications and mechanisms of action in cutaneous T-cell lymphoma (2003) Dermatol Ther, 16 (4), pp. 322-330
• Weinstock, M.A., Bingham, S.F., Digiovanna, J.J., Rizzo, A.E., Marcolivio, K., Hall, R., Tretinoin and the prevention of keratinocyte carcinoma (basal and squamous cell carcinoma of the skin): a veterans affairs randomized chemoprevention trial (2012) J Invest Dermatol, 132 (6), pp. 1583-1590
• Bodsworth, N.J., Bloch, M., Bower, M., Donnell, D., Yocum, R., Phase III vehicle-controlled, multi-centered study of topical alitretinoin gel 0.1% in cutaneous AIDS-related Kaposi's sarcoma (2001) Am J Clin Dermatol, 2 (2), pp. 77-87
• Miles, S.A., Dezube, B.J., Lee, J.Y., Krown, S.E., Fletcher, M.A., Saville, M.W., Antitumor activity of oral 9-cis-retinoic acid in HIV-associated Kaposi's sarcoma (2002) AIDS, 16 (3), pp. 421-429
• Recchia, F., Lalli, A., Lombardo, M., De Filippis, S., Saggio, G., Fabbri, F., Ifosfamide, cisplatin, and 13-cis retinoic acid for patients with advanced or recurrent squamous cell carcinoma of the head and neck: a phase I-II study (2001) Cancer, 92 (4), pp. 814-821
• Atzpodien, J., Kirchner, H., Jonas, U., Bergmann, L., Schott, H., Heynemann, H., Interleukin-2-and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a prospectively randomized trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy group (DGCIN) (2004) J Clin Oncol, 22 (7), pp. 1188-1194
• Straus, D.J., Duvic, M., Kuzel, T., Horwitz, S., Demierre, M.F., Myskowski, P., Results of a phase II trial of oral bexarotene (Targretin) combined with interferon alfa-2b (Intron-A) for patients with cutaneous T-cell lymphoma (2007) Cancer, 109 (9), pp. 1799-1803
• Quereux, G., Saint-Jean, M., Peuvrel, L., Brocard, A., Knol, A.C., Dreno, B., Bexarotene in cutaneous T-cell lymphoma: third retrospective study of long-term cohort and review of the literature (2013) Expert Opin Pharmacother, 14 (13), pp. 1711-1721
• Matthay, K.K., Reynolds, C.P., Seeger, R.C., Shimada, H., Adkins, E.S., Haas-Kogan, D., Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a Children's Oncology Group study (2009) J Clin Oncol, 27 (7), pp. 1007-1013
• Arrieta, O., Gonzalez-De la Rosa, C.H., Arechaga-Ocampo, E., Villanueva-Rodriguez, G., Ceron-Lizarraga, T.L., Martinez-Barrera, L., Randomized phase II trial of all-trans-retinoic acid with chemotherapy based on paclitaxel and cisplatin as first-line treatment in patients with advanced non-small-cell lung cancer (2010) J Clin Oncol, 28 (21), pp. 3463-3471
• Douer, D., Zickl, L.N., Schiffer, C.A., Appelbaum, F.R., Feusner, J.H., Shepherd, L., All-trans retinoic acid and late relapses in acute promyelocytic leukemia: very long-term follow-up of the North American Intergroup study I0129 (2013) Leuk Res, 37 (7), pp. 795-801
• Lo-Coco, F., Avvisati, G., Vignetti, M., Thiede, C., Orlando, S.M., Iacobelli, S., Retinoic acid and arsenic trioxide for acute promyelocytic leukemia (2013) N Engl J Med, 369 (2), pp. 111-121
• Dennert, G., Immunostimulation by retinoic acid (1985) Ciba Found Symp, 113, pp. 117-131
• Rhodes, S.J., Chen, R., DiMattia, G.E., Scully, K.M., Kalla, K.A., Lin, S.C., A tissue-specific enhancer confers Pit-1-dependent morphogen inducibility and autoregulation on the pit-1 gene (1993) Genes Dev, 7 (6), pp. 913-932
• Sanno, N., Sugawara, A., Teramoto, A., Abe, Y., Yen, P.M., Chin, W.W., Immunohistochemical expression of retinoid X receptor isoforms in human pituitaries and pituitary adenomas (1997) Neuroendocrinology, 65 (4), pp. 299-306
• Drouin, J., Maira, M., Philips, A., Novel mechanism of action for Nur77 and antagonism by glucocorticoids: a convergent mechanism for CRH activation and glucocorticoid repression of POMC gene transcription (1998) J Steroid Biochem Mol Biol, 65 (1-6), pp. 59-63
• Brown, N.S., Smart, A., Sharma, V., Brinkmeier, M.L., Greenlee, L., Camper, S.A., Thyroid hormone resistance and increased metabolic rate in the RXR-gamma-deficient mouse (2000) J Clin Invest, 106 (1), pp. 73-79
• Brossaud, J., Pallet, V., Corcuff, J.B., Vitamin A, endocrine tissues and hormones: interplay and interactions (2017) Endocr Connect, 6 (7), pp. R121-R130
• Napoli, J.L., Cellular retinoid binding-proteins, CRBP, CRABP, FABP5: effects on retinoid metabolism, function and related diseases (2017) Pharmacol Ther, 173, pp. 19-33
• Germain, P., Chambon, P., Eichele, G., Evans, R.M., Lazar, M.A., Leid, M., International union of pharmacology. LX. Retinoic acid receptors (2006) Pharmacol Rev, 58 (4), pp. 712-725
• Heyman, R.A., Mangelsdorf, D.J., Dyck, J.A., Stein, R.B., Eichele, G., Evans, R.M., 9-cis retinoic acid is a high affinity ligand for the retinoid X receptor (1992) Cell, 68 (2), pp. 397-406
• Whitfield, G.K., Jurutka, P.W., Haussler, C.A., Haussler, M.R., Steroid hormone receptors: evolution, ligands, and molecular basis of biologic function (1999) J Cell Biochem Suppl, 32-33, pp. 110-122
• Williams, G.R., Franklyn, J.A., Physiology of the steroid-thyroid hormone nuclear receptor superfamily (1994) Baillieres Clin Endocrinol Metab, 8 (2), pp. 241-266
• Wei, L.N., Cellular retinoic acid binding proteins: genomic and non-genomic functions and their regulation (2016) Subcell Biochem, 81, pp. 163-178
• Liu, Z., Hu, Q., Rosenfeld, M.G., Complexity of the RAR-mediated transcriptional regulatory programs (2014) Subcell Biochem, 70, pp. 203-225
• Piskunov, A., Al Tanoury, Z., Rochette-Egly, C., Nuclear and extra-nuclear effects of retinoid acid receptors: how they are interconnected (2014) Subcell Biochem, 70, pp. 103-127
• Wang, L.H., Tsai, S.Y., Cook, R.G., Beattie, W.G., Tsai, M.J., O'Malley, B.W., COUP transcription factor is a member of the steroid receptor superfamily (1989) Nature, 340 (6229), pp. 163-166
• Tsai, S.Y., Tsai, M.J., Chick ovalbumin upstream promoter-transcription factors (COUP-TFs): coming of age (1997) Endocr Rev, 18 (2), pp. 229-240
• Qiu, Y., Cooney, A.J., Kuratani, S., DeMayo, F.J., Tsai, S.Y., Tsai, M.J., Spatiotemporal expression patterns of chicken ovalbumin upstream promoter-transcription factors in the developing mouse central nervous system: evidence for a role in segmental patterning of the diencephalon (1994) Proc Natl Acad Sci U S A, 91 (10), pp. 4451-4455
• Pereira, F.A., Qiu, Y., Tsai, M.J., Tsai, S.Y., Chicken ovalbumin upstream promoter transcription factor (COUP-TF): expression during mouse embryogenesis (1995) J Steroid Biochem Mol Biol, 53 (1-6), pp. 503-508
• Qin, J., Suh, J.M., Kim, B.J., Yu, C.T., Tanaka, T., Kodama, T., The expression pattern of nuclear receptors during cerebellar development (2007) Dev Dyn, 236 (3), pp. 810-820
• Ip, B.K., Wappler, I., Peters, H., Lindsay, S., Clowry, G.J., Bayatti, N., Investigating gradients of gene expression involved in early human cortical development (2010) J Anat, 217 (4), pp. 300-311
• Kliewer, S.A., Umesono, K., Heyman, R.A., Mangelsdorf, D.J., Dyck, J.A., Evans, R.M., Retinoid X receptor-COUP-TF interactions modulate retinoic acid signaling (1992) Proc Natl Acad Sci U S A, 89 (4), pp. 1448-1452
• Tran, P., Zhang, X.K., Salbert, G., Hermann, T., Lehmann, J.M., Pfahl, M., COUP orphan receptors are negative regulators of retinoic acid response pathways (1992) Mol Cell Biol, 12 (10), pp. 4666-4676
• Park, J.I., Tsai, S.Y., Tsai, M.J., Molecular mechanism of chicken ovalbumin upstream promoter-transcription factor (COUP-TF) actions (2003) Keio J Med, 52 (3), pp. 174-181
• Fjose, A., Weber, U., Mlodzik, M., A novel vertebrate svp-related nuclear receptor is expressed as a step gradient in developing rhombomeres and is affected by retinoic acid (1995) Mech Dev, 52 (2-3), pp. 233-246
• Brubaker, K., McMillan, M., Neuman, T., Nornes, H.O., All-trans retinoic acid affects the expression of orphan receptors COUP-TF I and COUP-TF II in the developing neural tube (1996) Brain Res Dev Brain Res, 93 (1-2), pp. 198-202
• Jonk, L.J., de Jonge, M.E., Pals, C.E., Wissink, S., Vervaart, J.M., Schoorlemmer, J., Cloning and expression during development of three murine members of the COUP family of nuclear orphan receptors (1994) Mech Dev, 47 (1), pp. 81-97
• van der Wees, J., Matharu, P.J., de Roos, K., Destree, O.H., Godsave, S.F., Durston, A.J., Developmental expression and differential regulation by retinoic acid of Xenopus COUP-TF-A and COUP-TF-B (1996) Mech Dev, 54 (2), pp. 173-184
• Zhuang, Y., Gudas, L.J., Overexpression of COUP-TF1 in murine embryonic stem cells reduces retinoic acid-associated growth arrest and increases extraembryonic endoderm gene expression (2008) Differentiation, 76 (7), pp. 760-771
• Luo, J., Sucov, H.M., Bader, J.A., Evans, R.M., Giguere, V., Compound mutants for retinoic acid receptor (RAR) beta and RAR alpha 1 reveal developmental functions for multiple RAR beta isoforms (1996) Mech Dev, 55 (1), pp. 33-44
• Qiu, Y., Pereira, F.A., DeMayo, F.J., Lydon, J.P., Tsai, S.Y., Tsai, M.J., Null mutation of mCOUP-TFI results in defects in morphogenesis of the glossopharyngeal ganglion, axonal projection, and arborization (1997) Genes Dev, 11 (15), pp. 1925-1937
• Alfano, C., Magrinelli, E., Harb, K., Studer, M., The nuclear receptors COUP-TF: a long-lasting experience in forebrain assembly (2014) Cell Mol Life Sci, 71 (1), pp. 43-62
• Paez-Pereda, M., Kovalovsky, D., Hopfner, U., Theodoropoulou, M., Pagotto, U., Uhl, E., Retinoic acid prevents experimental Cushing syndrome (2001) J Clin Invest, 108 (8), pp. 1123-1131
• Uruno, A., Saito-Hakoda, A., Yokoyama, A., Kogure, N., Matsuda, K., Parvin, R., Retinoic acid receptor-alpha up-regulates proopiomelanocortin gene expression in AtT20 corticotroph cells (2014) Endocr J, 61 (11), pp. 1105-1114
• Giacomini, D., Paez-Pereda, M., Theodoropoulou, M., Labeur, M., Refojo, D., Gerez, J., Bone morphogenetic protein-4 inhibits corticotroph tumor cells: involvement in the retinoic acid inhibitory action (2006) Endocrinology, 147 (1), pp. 247-256
• Tsukamoto, N., Otsuka, F., Miyoshi, T., Yamanaka, R., Inagaki, K., Yamashita, M., Effects of bone morphogenetic protein (BMP) on adrenocorticotropin production by pituitary corticotrope cells: involvement of up-regulation of BMP receptor signaling by somatostatin analogs (2010) Endocrinology, 151 (3), pp. 1129-1141
• Yacqub-Usman, K., Duong, C.V., Clayton, R.N., Farrell, W.E., Preincubation of pituitary tumor cells with the epidrugs zebularine and trichostatin A are permissive for retinoic acid-augmented expression of the BMP-4 and D2R genes (2013) Endocrinology, 154 (5), pp. 1711-1721
• Sesta, A., Cassarino, M.F., Tapella, L., Castelli, L., Cavagnini, F., Pecori Giraldi, F., Effect of retinoic acid on human adrenal corticosteroid synthesis (2016) Life Sci, 151, pp. 277-280
• Ling, G.V., Stabenfeldt, G.H., Comer, K.M., Gribble, D.H., Schechter, R.D., Canine hyperadrenocorticism: pretreatment clinical and laboratory evaluation of 117 cases (1979) J Am Vet Med Assoc, 174 (11), pp. 1211-1215
• Castillo, V., Giacomini, D., Paez-Pereda, M., Stalla, J., Labeur, M., Theodoropoulou, M., Retinoic acid as a novel medical therapy for Cushing's disease in dogs (2006) Endocrinology, 147 (9), pp. 4438-4444
• De Marco, V., Pinto, E.M., Mendoca, B.B., (2009) Nelson's syndrome in a poodle dog treated with retinoic acid, p. 34. , World Small Animal Veterinary Association World Congress 2009. São Paulo, Brazil
• Layton, A., The use of isotretinoin in acne (2009) Dermatoendocrinol, 1 (3), pp. 162-169
• Bush, Z.M., Lopes, M.B., Hussaini, I.M., Jane, J.A., Jr., Laws, E.R., Jr., Vance, M.L., Immunohistochemistry of COUP-TFI: an adjuvant diagnostic tool for the identification of corticotroph microadenomas (2010) Pituitary, 13 (1), pp. 1-7
• Wu, Q., Li, Y., Liu, R., Agadir, A., Lee, M.O., Liu, Y., Modulation of retinoic acid sensitivity in lung cancer cells through dynamic balance of orphan receptors nur77 and COUP-TF and their heterodimerization (1997) EMBO J, 16 (7), pp. 1656-1669

Citas:

---------- APA ----------

---------- CHICAGO ----------

---------- MLA ----------

---------- VANCOUVER ----------